As tropical viruses increase in the US, Infection Control Today wanted to learn more about chikungunya. Here is what we learned.
As tropical viruses show up more often in the United States, Infection Control Today® (ICT®) wanted to get more information about one virus in particular: the chikungunya. To learn more, ICT spoke with Thomas Rademacher, MD, PhD, cofounder of Emergex, who has served as CEO since the company's formation. He is also an emeritus professor of Molecular Medicine at University College London.
Rademacher explains the virus, related viruses, and how Emergex recently signed a contract with the UK Department of Health and Social Care to advance a CD8 T cell-based vaccine candidate against chikungunya.
Chikungunya virus, 3D illustration. Emerging mosquito-borne RNA virus from Togaviridae family that can cause outbreaks of a debilitating arthritis-like disease
(Adobe Stock 126688070 by Dr Microbe)
Chikungunya is a viral disease from the Togavirdidae genus Alphavirus that has gained increasing attention in recent years due to its rapid spread and debilitating effects on individuals. This infectious disease is primarily transmitted to humans through the bite of infected Aedes mosquitoes, primarily Aedes aegypti and Aedes albopictus. Chikungunya is characterized by a sudden onset of high fever, severe joint pain, and a range of other influenza-like symptoms, making it challenging to diagnose accurately. While it is not typically fatal, the acute phase of the illness can be extremely distressing and incapacitating, often leaving individuals bedridden for weeks.
The name "chikungunya" is derived from the Kimakonde language, meaning "to become contorted," which aptly describes the painful joint deformities that can result from the infection.
“Therefore, to generate types of vaccines that will have broad specificity will cross-react, but we're acting with more than one because it's just not practical,” Rademacher said. “If people go to endemic regions where mosquitoes are, you don't know what you're going to get there….The idea here is to use chikungunya as sort of a prototype and develop a vaccine against that. But the hope is, of course, that vaccine will cover other members of the chikungunya family.”
“Ongoing Assault”: How HHS Layoffs Have Eviscerated Infection Prevention Support Across the Nation
April 1st 2025Mass layoffs at HHS and CDC have gutted critical infection prevention programs, leaving frontline professionals overwhelmed, under-resourced, and desperate to safeguard public health.
Together We Rise: Why AORN Expo 2025 Is a Must for Every Perioperative Nurse
March 31st 2025From April 5 to 8, 2025, thousands of perioperative nurses will gather in Boston for the 2025 AORN Global Surgical Conference & Expo—a transformational experience designed to elevate nursing practice, build lifelong connections, and advance surgical care.
Vet IP Roundtable 2: Infection Control and Biosecurity Challenges in Veterinary Care
March 31st 2025Veterinary IPs highlight critical gaps in cleaning protocols, training, and biosecurity, stressing the urgent need for standardized, animal-specific infection prevention practices across diverse care settings.